Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on adding value to medicines used in Critical Care situations.
Discover Ethypharm at a glance
Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring that people in need are able to receive the right treatment at the right time and with the right support.
Ethypharm is deeply engaged in the CNS and Critical Care areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our 2 core therapeutic areas.
Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!
Ethypharm ready to bring to patients world-leading digital therapies for depression and addiction
On April 6, 2021 Ethypharm announced that it has acquired exclusive rights in several European countries for two CE-marked digital therapies, deprexis® and vorvida®, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm partners with Clever Leaves for medical cannabis products in Germany
On March 17, 2021 Ethypharm signed an exclusive license agreement with Clever Leaves for the distribution and sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. For Ethypharm, this is a further step to become a leading and trusted provider of medical cannabis products in Europe.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.
Linked